Advertisement
UK markets closed
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    82.68
    -0.13 (-0.16%)
     
  • GOLD FUTURES

    2,342.80
    +4.40 (+0.19%)
     
  • DOW

    38,002.13
    -458.79 (-1.19%)
     
  • Bitcoin GBP

    51,510.66
    -388.49 (-0.75%)
     
  • CMC Crypto 200

    1,397.10
    +14.53 (+1.05%)
     
  • NASDAQ Composite

    15,536.00
    -176.75 (-1.12%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

NMC Health Plc’s (LON:NMC) Investment Returns Are Lagging Its Industry

Today we’ll evaluate NMC Health Plc (LON:NMC) to determine whether it could have potential as an investment idea. In particular, we’ll consider its Return On Capital Employed (ROCE), as that can give us insight into how profitably the company is able to employ capital in its business.

First of all, we’ll work out how to calculate ROCE. Next, we’ll compare it to others in its industry. Finally, we’ll look at how its current liabilities affect its ROCE.

Understanding Return On Capital Employed (ROCE)

ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business. In general, businesses with a higher ROCE are usually better quality. Overall, it is a valuable metric that has its flaws. Author Edwin Whiting says to be careful when comparing the ROCE of different businesses, since ‘No two businesses are exactly alike.’

So, How Do We Calculate ROCE?

The formula for calculating the return on capital employed is:

ADVERTISEMENT

Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets – Current Liabilities)

Or for NMC Health:

0.12 = US$283m ÷ (US$3.6b – US$837m) (Based on the trailing twelve months to June 2018.)

So, NMC Health has an ROCE of 12%.

See our latest analysis for NMC Health

Want to help shape the future of investing tools and platforms? Take the survey and be part of one of the most advanced studies of stock market investors to date.

Does NMC Health Have A Good ROCE?

When making comparisons between similar businesses, investors may find ROCE useful. It appears that NMC Health’s ROCE is fairly close to the Healthcare industry average of 11%. Separate from NMC Health’s performance relative to its industry, its ROCE in absolute terms looks satisfactory, and it may be worth researching in more depth.

LSE:NMC Last Perf January 16th 19
LSE:NMC Last Perf January 16th 19

It is important to remember that ROCE shows past performance, and is not necessarily predictive. ROCE can be deceptive for cyclical businesses, as returns can look incredible in boom times, and terribly low in downturns. ROCE is, after all, simply a snap shot of a single year. Future performance is what matters, and you can see analyst predictions in our free report on analyst forecasts for the company.

Do NMC Health’s Current Liabilities Skew Its ROCE?

Liabilities, such as supplier bills and bank overdrafts, are referred to as current liabilities if they need to be paid within 12 months. Due to the way the ROCE equation works, having large bills due in the near term can make it look as though a company has less capital employed, and thus a higher ROCE than usual. To check the impact of this, we calculate if a company has high current liabilities relative to its total assets.

NMC Health has total liabilities of US$837m and total assets of US$3.6b. As a result, its current liabilities are equal to approximately 23% of its total assets. Low current liabilities are not boosting the ROCE too much.

Our Take On NMC Health’s ROCE

This is good to see, and with a sound ROCE, NMC Health could be worth a closer look. You might be able to find a better buy than NMC Health. If you want a selection of possible winners, check out this free list of interesting companies that trade on a P/E below 20 (but have proven they can grow earnings).

I will like NMC Health better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.